Benzinga | Jul 1, 2021 08:35AM EDT

ReShape Lifesciences Says Utilization Of Its Lap-Band Increased During COVID-19 Pandemic

ReShape Lifesciences Inc. (NASDAQ:RSLS), the premier physician-led weight-loss solutions company, today announced that Lap-Band(r) utilization has increased since COVID-19 in response to patients' increased desire for a reimbursed, effective, and sustainable weight-loss procedure that can be provided in outpatient surgery centers. The Lap-Band is clinically proven to be the safest bariatric procedure available on the market,backed by over 20 years of data demonstrating lower complication and mortality rates compared to other surgical weight-loss procedures. The Lap-Band is also the only FDA-approved, laparoscopic weight-loss device specifically indicated for lower Body Mass Indexes of 30 or higher in the U.S. Following this procedural growth and the favorable evaluation of recent and historical consumer focused marketing efforts, with Lap-Band annual revenue of approximately $300M at one time, the company intends to significantly enhance and broaden patient-direct advertising and promotion.